| Name | Etamicastat hydrochloride |
| Description | Etamicastat hydrochloride (BIA 5-453 hydrochloride) is a peripherally selective dopamine beta-hydroxylase inhibitor that reduces hypertension. |
| Cell Research | Etamicastat blocks the hERG current amplitude with an IC50 value of 44 μg/mL . |
| Animal Research | Etamicastat (50 mg/kg; a single oral administration) exhibits moderate oral bioavailability (64%), Cmax (4.9 nM), and terminal elimination half-lives (T1/2=3.7 h) in male Wistar rats.Etamicastat (100 mg/kg; administered intraperitoneally) leads to a significant reduction of noradrenaline levels in heart with concomitant increasing in dopamine levels. |
| In vitro | Etamicastat hydrochloride blocks the hERG current amplitude with an IC50 value of 44 μg/mL [1]. |
| In vivo | Etamicastat hydrochloride (50 mg/kg; a single oral administration) exhibits moderate oral bioavailability (64%), Cmax (4.9 nM), and terminal elimination half-lives (T1/2=3.7 h) in male Wistar rats.Etamicastat hydrochloride (100 mg/kg; administered intraperitoneally) leads to a significant reduction of noradrenaline levels in heart with concomitant increasing in dopamine levels[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : 15.0 mg/mL (43.1 mM), Sonication is recommended.
DMSO : 90.0 mg/mL (258.8 mM), Sonication is recommended.
|
| Keywords | Etamicastat Hydrochloride | BIA 5-453 Hydrochloride |
| Inhibitors Related | Disulfiram | Methotrexate | Rotenone | Mycophenolate Mofetil | Ribavirin | 4-Diethylaminobenzaldehyde | Benzyl alcohol | Isomalt | Isoniazid | Ivosidenib |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max |
United States
